GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Down 76.9% in June

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 62,850 shares, a drop of 76.9% from the June 15th total of 271,752 shares. Approximately 1.8% of the shares of the stock are sold short. Based on an average trading volume of 436,362 shares, the short-interest ratio is currently 0.1 days.

GeoVax Labs Price Performance

Shares of GOVX traded up $0.01 during mid-day trading on Friday, hitting $1.18. The company’s stock had a trading volume of 87,745 shares, compared to its average volume of 356,370. The firm has a 50-day moving average price of $1.65 and a 200 day moving average price of $2.09. The stock has a market capitalization of $4.09 million, a price-to-earnings ratio of -0.06 and a beta of 3.68. GeoVax Labs has a fifty-two week low of $0.96 and a fifty-two week high of $23.10.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Wednesday, April 15th. The company reported $1.85 EPS for the quarter. As a group, equities analysts anticipate that GeoVax Labs will post -8.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on GOVX. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a report on Tuesday, April 21st. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. Finally, Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, GeoVax Labs has a consensus rating of “Reduce” and an average target price of $150.00.

Hedge Funds Weigh In On GeoVax Labs

Hedge funds have recently modified their holdings of the stock. Sabby Management LLC acquired a new stake in shares of GeoVax Labs during the third quarter worth $313,000. Renaissance Technologies LLC acquired a new position in shares of GeoVax Labs in the 4th quarter valued at $104,000. Jane Street Group LLC purchased a new position in GeoVax Labs in the 4th quarter worth about $99,000. Armistice Capital LLC purchased a new position in GeoVax Labs in the 3rd quarter worth about $253,000. Finally, HRT Financial LP acquired a new stake in GeoVax Labs during the 4th quarter worth about $31,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.